Q.01

What does the FDA require when a drug batch fails a quality test?

FDA requires the batch to be rejected and the failure investigated in writing, under the CGMP rules for finished drugs (21 CFR Part 211). The investigation must also cover other batches and products that may be affected, even if the failed batch has already shipped. If a distributed batch of an approved NDA or ANDA product fails its application specification, the applicant must also send FDA a Field Alert Report within 3 working days.

1. Reject the batch. Drug products that fail "established standards or specifications and any other relevant quality control criteria shall be rejected" [1]. Each batch needs lab confirmation that it meets final specifications, including identity and strength of each active ingredient, before release. The only exception in the rule is short-lived radiopharmaceuticals awaiting sterility or pyrogen results [2]. Failed in-process materials, components, containers and closures "shall be identified and controlled under a quarantine system" so they cannot be used [3][4].

2. Investigate (§ 211.192). These points come from the production record review rule [5]:

  • The failure of a batch, or any of its components, to meet a specification "shall be thoroughly investigated, whether or not the batch has already been distributed."
  • The investigation "shall extend to other batches of the same drug product and other drug products that may have been associated with the specific failure."
  • A written record of the investigation "shall be made and shall include the conclusions and followup."
  • The quality control unit must review and approve the records before any batch is released.

3. Quality unit authority. The quality control unit has the authority to approve or reject drug products. It must make sure errors "have been fully investigated," including for products made under contract by another company [6]. Any departure from written procedures or lab controls "shall be recorded and justified" [7][8].

4. Reprocessing is allowed, with controls.

  • "Reprocessing may be performed," but reprocessed material "must meet appropriate standards, specifications, and any other relevant criteria" before it is accepted [1].
  • It must follow written reprocessing procedures [9].
  • It "shall not be performed without the review and approval of the quality control unit" [10].

5. Annual product review. The yearly quality review must cover a representative number of batches, "whether approved or rejected" [11]. It must also cover complaints, recalls, and the § 211.192 investigations for each product [12].

6. Field Alert Report, if the batch was distributed (§ 314.81(b)(1)).

  • Applicants must report "any failure of one or more distributed batches of the drug product to meet the specification established for it in the application."
  • The report goes to the FDA district office responsible for the facility, "within 3 working days of receipt by the applicant."
  • It may be made by telephone or other rapid means, "with prompt written followup," marked "NDA—Field Alert Report" [13].
  • ANDA holders must make the same § 314.81 reports [14].
  • FDA's Field Alert Reports page says to submit Form FDA 3331a to that district office.

Guidance. How FDA expects an out-of-specification (OOS) result to be investigated is set out in its final guidance Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production (Level 2 revision, May 2022, docket FDA-1998-D-0019). It covers results outside specifications set in applications, drug master files, official compendia or by the manufacturer, including in-process tests. FDA also has a July 2021 guidance, Field Alert Report Submission: Questions and Answers (docket FDA-2018-D-2326). I couldn't open the text of either document, so I haven't described their detailed advice (lab investigation phases, retesting, averaging, when an OOS triggers a Field Alert Report).

Approach: I worked from the current eCFR text of 21 CFR Parts 210/211 and Part 314, plus FDA's own pages on OOS investigations and Field Alert Reports. This covers human drugs approved under NDAs and ANDAs; I didn't check the separate reporting rules for biologics.

Q.02

When can we release a batch after an investigation?

Under 21 CFR Part 211, the investigation itself does not clear a batch for release. The batch can only be released once three things are true: the quality control unit has reviewed and approved the production and control records; lab testing shows the batch meets its final specifications; and the batch has passed the acceptance criteria. If the batch truly failed a specification, it "shall be rejected." Its only route back to release is reprocessing that the quality control unit approves, followed by passing results on the reprocessed material.

What must be in place before release

  • Quality control unit sign-off on the records. All production and control records, including packaging and labeling, "shall be reviewed and approved by the quality control unit… before a batch is released or distributed." The same section requires the failure investigation, which must cover other batches and products that may be affected. It also requires a written record that "shall include the conclusions and followup" [5]. In practice, the investigation has to be finished and documented, with conclusions, before the quality control unit can approve the records.
  • Passing lab results. There "shall be appropriate laboratory determination of satisfactory conformance to final specifications," including identity and strength of each active ingredient, "prior to release" [2].
  • Meeting the acceptance criteria. Sampling and testing criteria must ensure batches meet "each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release" [15].
  • Quarantine until then. Your warehousing procedures must provide for "quarantine of drug products before release by the quality control unit" [16].

If the investigation confirms the failure

  • The batch "shall be rejected." "Reprocessing may be performed," but before the reprocessed material is accepted and used it "must meet appropriate standards, specifications, and any other relevant criteria" [1].
  • Reprocessing must follow written procedures that set out the steps to make sure reprocessed batches meet all established standards and specifications [9]. It "shall not be performed without the review and approval of the quality control unit" [10].
  • The final decision rests with the quality control unit, which has "the responsibility and authority to approve or reject" drug products. It must also make sure any errors "have been fully investigated," including for products made under contract [6].
  • Any departure from written specifications or test procedures "shall be recorded and justified" [8].

What Part 211 doesn't cover

  • No time limit. None of the Part 211 sections I checked sets a deadline for finishing the investigation or deciding on release.
  • Invalidated results. Part 211 does not say when a failing result can be set aside, for example after confirmed lab error, so that a passing retest supports release. FDA's OOS guidance covers that. As in my last answer, I couldn't open its text, so I haven't described how it handles this.
  • Radiopharmaceuticals. The one exception to testing before release is for short-lived radiopharmaceuticals. They may be released before sterility or pyrogen testing is complete, "provided such testing is completed as soon as possible" [2].

Approach: I worked from the current eCFR text of 21 CFR Part 211 (testing and release, production record review, quality control unit, reprocessing, laboratory controls and warehousing). This covers finished human drugs; I didn't check biologics-specific release rules.

Q.03